enVVeno Medical (NVNO)
NASDAQ:NVNO
Want to see NVNO full AI Analyst Report?
NVNO Stock Chart & Stats
$0.36
-$0.06(-1.92%)
At close: 4:00 PM EST
$0.36
-$0.06(-1.92%)
Day’s Range― - ―
52-Week Range$8.67 - $196.70
Previous CloseN/A
Volume33.14K
Average Volume (3M)589.93K
Market Cap
$7.32M
Enterprise Value-$1.81M
Total Cash (Recent Filing)$24.93M
Total Debt (Recent Filing)$603.00K
Price to Earnings (P/E)―
Beta1.74
Next Earnings
Jul 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-697.80
Shares Outstanding667,669
10 Day Avg. Volume395,892
30 Day Avg. Volume589,933
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.25
Price to Sales (P/S)0.00
P/FCF Ratio-0.43
Enterprise Value/Market Cap-0.25
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit3.69
Enterprise Value/Ebitda0.09
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-35
Revenue Forecast (FY)$7.00M
Bulls Say, Bears Say
Bulls Say
FDA IDE Approval For TAVVE Pivotal TrialAn FDA IDE is a structural regulatory milestone enabling a U.S. pivotal trial and a clear pathway toward post‑market approval. Over 2–6 months it materially de-risks clinical development, allows generation of pivotal data, and strengthens future commercial and partnership prospects.
Low Financial LeverageVery low debt provides durable financial flexibility: it reduces solvency risk while the company executes trials, limiting interest burden and preserving capacity to raise capital on clinical milestones rather than servicing debt, which supports longer runway for development.
Cash Runway To Q3 2027 (~$25M)A disclosed cash balance funding operations into Q3 2027 provides a multiquarter runway to complete early stages of the pivotal program, pursue enrollment, and deliver interim data. That runway reduces near‑term financing urgency and supports execution of strategic clinical objectives.
Bears Say
Pre‑revenue, Persistent LossesBeing pre‑revenue while incurring sizable losses is a structural business risk: without commercialization, the company must finance operations externally. This reliance increases dilution risk and makes long‑term viability contingent on successful regulatory and commercial execution.
Weak Cash Generation / Negative FCFSustained negative operating and free cash flow signals the company cannot self‑fund growth and will need fresh capital to scale. Over months this constrains investment in commercialization, manufacturing scale‑up, or broader clinical programs absent partnerships or financing.
Erosion Of Equity And Negative ReturnsMaterial declines in equity and assets, coupled with deeply negative ROE, indicate the company is eroding shareholder capital through operations. This structural deterioration reduces financial resilience and may force dilutive capital raises or strategic tradeoffs over the medium term.
enVVeno Medical News
NVNO FAQ
What was enVVeno Medical’s price range in the past 12 months?
enVVeno Medical lowest stock price was $8.67 and its highest was $196.70 in the past 12 months.
What is enVVeno Medical’s market cap?
enVVeno Medical’s market cap is $7.32M.
When is enVVeno Medical’s upcoming earnings report date?
enVVeno Medical’s upcoming earnings report date is Jul 30, 2026 which is in 66 days.
How were enVVeno Medical’s earnings last quarter?
enVVeno Medical released its earnings results on May 04, 2026. The company reported -$5.885 earnings per share for the quarter, missing the consensus estimate of N/A by -$5.885.
Is enVVeno Medical overvalued?
According to Wall Street analysts enVVeno Medical’s price is currently Overvalued.
Does enVVeno Medical pay dividends?
enVVeno Medical does not currently pay dividends.
What is enVVeno Medical’s EPS estimate?
enVVeno Medical’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does enVVeno Medical have?
enVVeno Medical has 667,669 shares outstanding.
What happened to enVVeno Medical’s price movement after its last earnings report?
enVVeno Medical reported an EPS of -$5.885 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.714%.
Which hedge fund is a major shareholder of enVVeno Medical?
Currently, no hedge funds are holding shares in NVNO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
enVVeno Medical
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. The company's lead product is the VenoValve, a replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Technical Analysis
Ownership Overview
9.48% Insiders
0.97% Mutual Funds
10.77% Other Institutional Investors
77.64% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---